Krka UK has announced the launch of Arocenia® 10 mg/ml injectable solution, a new addition to its expanding portfolio of generic pharmaceuticals. Containing the active ingredient maropitant, a neurokinin-1 (NK1) receptor antagonist, Arocenia® is licensed for the prevention and treatment of vomiting in dogs and cats, including perioperative use and chemotherapy-associated indications in dogs.
Unveiled at BVA Live 2025, Arocenia® provides fast, broad-spectrum anti-emetic efficacy with a 24-hour duration of action following a single daily dose. It can be administered intravenously or subcutaneously and is supplied in 20 ml multi-dose vials, allowing up to 40 punctures per vial and a 60-day open vial shelf life.
Renzo Di Florio, Krka’s Technical Veterinary Adviser, commented “Vomiting is one of the most common presenting signs in small animal practice, and maropitant is a medication you’ll find on just about every vet’s dispensary shelf. With Arocenia®, we’re adding a cost-effective formulation to the available options.”
Arocenia® supports a wide range of clinical applications, including the prevention of perioperative nausea and vomiting and improving recovery from general anaesthesia after the use of the u-receptor agonist, morphine. It also provides important antiemetic support during chemotherapy and is indicated for prevention of nausea and vomiting in cats across varied clinical contexts. Its broad indication range make it a useful option for busy small animal clinics.
Will Ridgway, Head of Animal Health at Krka UK, added “With so many pressures on practice workflow, having products that are accessible, cost-effective and reliable is essential. Arocenia® reflects that approach – and because we manage our own manufacturing in Europe, we can offer the consistency and supply reassurance that veterinary teams rely on.”
Krka continues to innovate in the animal medicine category with new generic formulations. The launch of Arocenia® further strengthens Krka’s commitment to providing practical, evidence-based solutions that support both patient outcomes and practice efficiency.
For more information visit https://www.krka.co.uk//products/our-products/animal-health/arocenia-10mgml-solution-for-injection/
For further details contact KRKA UK by emailing animalhealth.uk@krka.biz.
Press contact: Katy Ellison, katy@companionconsultancy.com, Tel 07596 217372.
About Krka
Krka partners closely with its customers to provide licensed medicines that are proven in clinical practice. With European-based manufacturing, the company ensures high-quality production standards, while its vertically integrated R&D and supply chain enable rapid response to market needs and consistent product availability. Supported by a dedicated sales team, Krka’s animal health portfolio includes well-established and effective treatments for both companion and food-producing animals. Key brands include Milprazon CHEWABLE® for comprehensive worm control in dogs and cats, and Tolracol® for managing coccidiosis in cattle and sheep. Recent innovations in the companion animal range feature Robexera® for targeted pain relief, Cladaxxa® for infection management, and Otomicol® for the treatment of otitis externa.
Leave a Reply